Jupiter Endovascular announced today that it closed an oversubscribed Series B financing that surpassed its target of $40 million.
Sonder Capital led the financing, while Senvest Management, LB Investment and a new strategic corporate investor participated.
Menlo Park, California-plans to use proceeds to complete its ongoing SPIRARE II pivotal clinical trial. Funds could also go toward preparing for commercialization and developing new clinical applications for its transforming fixation (TFX) platform technology.
The financing comes just weeks after the company received FDA clearance for its Vertex catheter incorporating TFX. Jupiter designed its Vertex system to treat acute pulmonary embolism (PE). The innovative endovascular procedure offers high levels of control and precision. It received FDA investigational device exemption in August 2024.
More about Jupiter Endovascular and TFX
Jupiter’s TFX platform brings stability and control to catheter interventions, the company says. It aims to enable interventionalists to treat anatomical sites usually not safely or easily accessible via conventional endovascular approaches.
Vertex delivery takes place in a flexible, relaxed state over a guidewire to a target location in the vasculature. Rapidly pressurized with saline, it fixes in a stable position for intervention. Then, it returns to a relaxed state to navigate to another target location or for removal.
Following clearance, the company plans to share first-in-human results for its Vertex pulmonary embolectomy system with TFX from the SPIRARE I trial at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2025) meeting later this month. The study enrolled 10 subjects with acute, intermediate-risk PE treated with Vertex.
Next, the company continues enrolling patients in SPIRARE II, a pivotal trial set to enroll up to 145 patients. The study evaluates Vertex in acute, intermediate-risk PE at up to 25 sites in the U.S. and Europe. Trial endpoints for both SPIRARE I and SPIRARE II could highlight the procedural and clinical benefits of PE treatment with TFX using the Vertex system. They span measures of safety, right heart function and clinical improvement from the time of the procedure to 30 days post-procedure.
Min-Vasive Medtech: Watch on-demand interviews and audience Q&As with minimally invasive engineers from Jupiter Endo, Edwards Lifesciences and Compremium
